Steven Cohen acquired 3.34M Immunovant shares worth $53.8M. That's 0.13% of their equity portfolio (203rd largest holding). The investor owns 2.10% of the outstanding Immunovant stock. The first Immunovant trade was made in Q1 2020. Since then Steven Cohen bought shares eight more times and sold shares on ten occasions. The investor's estimated purchase price is $55.2M, resulting in a loss of 2.6%.